Ranitidine, a gastric antacid drug, disappeared from drugstore shelves two years ago, due to fears of contamination with N-nitrosodimethylamine (NDMA), which is probably carcinogenic to humans.
In this episode of The PJ Pod, editor-in-chief Dawn Connelly finds out why.
She talks to David Light, CEO of Valisure, the online pharmacy that first identified ranitidine contamination, and Michael White, professor of pharmacy at the University of Connecticut, about the implications for other drugs. similar.
Connelly also assesses recent evidence that ranitidine may be on the verge of making a comeback and discusses the issues of switching to alternative treatments with Mikin Patel, Senior Gastroenterology Pharmacist at Imperial College Healthcare NHS Trust, London, and Alisdair Jones, Primary Care Network Pharmacist in Folkestone, Kent.
This episode was produced by Geoff Marsh and additional research was conducted by Emma Wilkinson.
Clinical advice on alternatives to ranitidine preparations for adults and children was shared by the Department of Health and Welfare in ranitidine supply disruption alert (see tables 1 and 2).